je.st
news
Tag: oncology
Genedata at SLAS2014 Announces New Data Analysis Platform for Next-Gen Oncology Drug Discovery
2014-01-20 06:00:00| Industrial Newsroom - All News for Today
AstraZeneca and Genedata will detail a data analysis platform for compound combination experiments in oncology and other therapeutic areas <br /> <br /> San Diego, Calif. – Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that at SLAS2014 it will showcase results from its collaboration with AstraZeneca on the data analysis of compound combination experiments. This collaboration created the new Genedata Screener® ...This story is related to the following:Scientific Software | Data Analysis Software |
Tags: data
analysis
drug
platform
Discovering The Pearls And Pitfalls Of Implementing Imaging In Multicentre Clinical Trials | Oncology Imaging For Drug Development
2013-12-04 05:03:28| drugdiscoveryonline News Articles
Powerful image analysis is a necessity to fully understand the true genetic and biological nature of a tumor. This can lead not only to less variability in interpretation and more accuracy in tumor mapping, but it also can help prevent cancer outgrowth based on genetic mutation
Tags: development
drug
clinical
implementing
Boston Strategics Announces Oncology Drug Development Partnership With FUJIFILM Pharmaceuticals U.S.A
2013-12-04 04:01:11| drugdiscoveryonline News Articles
Boston Strategics Corporation, an integrated research and development biotechnology company, Boston, MA, recently announced a new drug development partnership with FUJIFILM Pharmaceuticals U.S.A., Inc
Tags: development
usa
drug
partnership
Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in Journal of Clinical Oncology
2013-10-14 23:02:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind. Merck and Endocytes Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology. Language: English Contact: MerckMedia:Caroline Lappetito,267-305-7639Caroline.Lappetito@Merck.comorClaire Mulhearn, 908-423-7425Claire.Mulhearn@Merck.comorInvestors:Carol Ferguson, 908-423-4465Carol.Ferguson@Merck.comorJustin Holko, 908-423-5088Justin_Holko@Merck.comorEndocyteMedia:Tony Russo, 212-845-4251Tony.Russo@Russopartnersllc.comorMartina Schwarzkopf, 212-845-4292Martina.Schwarzkopf@Russopartnersllc.comorInvestors:Stephanie Ascher, 212-362-1200Stephanie@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more
Tags: of
results
journal
published
Bayer to Present Data on Multiple Oncology Compounds at the European...
2013-09-17 16:58:01| Chemicals - Topix.net
These data include an oral presentation of a subanalysis from the Phase III trial of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer, an oral presentation and posters on the efficacy and safety of regorafenib, which was recently approved by the European Medicines Agency , and posters on additional analyses ... (more)
Tags: the
data
present
multiple
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »